Investors Shift Stakes: Johnson & Johnson Sees Key Changes in Holdings

Sanibel, Florida, USA - On June 14, 2025, the financial landscape revealed intriguing shifts involving Johnson & Johnson (NYSE: JNJ). A noteworthy pivot occurred as the Sanibel Captiva Trust Company Inc. trimmed its stake in the pharmaceutical giant by 2.1% during the first quarter. After selling 8,166 shares, the trust now holds 382,944 shares, a reflection of its strategy amidst an environment filled with investor activity. Remarkably, J&J now constitutes about 2.1% of Sanibel Captiva Trust’s portfolio, making it their ninth-largest holding, valued at an impressive $63,507,000.

In addition to Sanibel’s sale, other investors have been adjusting their positions as well. For instance, Lantz Financial LLC increased its holdings in J&J by 3.3%, bringing its total shares to 11,974, valued at roughly $1,986,000. Meanwhile, Sulzberger Capital Advisors Inc. entered the fray with a new stake worth $453,000. Horan Securities Inc. and Strategic Financial Concepts LLC also stepped up their investments, the latter marvelously increasing its stake by a staggering 57.9%.

Investor Landscape

Notably, a whopping 69.55% of Johnson & Johnson’s stock is currently owned by hedge funds and institutional investors. This includes the State of Wyoming, which made a dramatic leap, boosting its stake by an astounding 205,580.0% to own 10,284 shares valued at $1,487,000. With such activity, it’s clear the stock remains a hot topic among institutional players.

The ever-watchful analysts have also made their evaluations known. After careful consideration, Leerink Partners downgraded their rating from „strong-buy“ to „hold.“ Yet, opinions differ across the board: Raymond James lowered their target price from $165.00 to $162.00 but sustained an „outperform“ rating, while Morgan Stanley raised its target price from $164.00 to $169.00, maintaining „equal weight.“ Meanwhile, Bank of America adjusted downwards from $171.00 to $159.00, keeping a „neutral“ stance. It appears there’s a consensus around a „Moderate Buy,“ with a target price averaging at $170.88.

Stock Performance and Earnings

As for the stock’s performance, trading at $156.90 with a robust volume of 6,587,488 shares, Johnson & Johnson boasts a market capitalization of $377.52 billion. Given the ups and downs, the stock has a 52-week low of $140.68 and a high of $169.99. The company reported earnings per share (EPS) of $2.77 for the last quarter, surpassing the consensus estimate of $2.59, and a revenue of $21.89 billion, exceeding expectations of $21.65 billion.

On the dividend front, J&J declared a quarterly dividend of $1.30, up from $1.24, reflecting its commitment to returning value to shareholders. The stock offers a dividend yield of 3.31% with a payout ratio of 57.84%. Such figures suggest a steady confidence in the company’s ability to generate returns.

As we navigate through these financial tides, it’s evident that Johnson & Johnson continues to command attention, balancing the scales of investor sentiment and market performance. Will the shifts in ownership sway future performance? Only time will tell, but for now, J&J remains a prominent figure in the investment world.